Abstract
It is well known that recombinant human granulocyte colony-stimulating factor (rHuG-CSF) is approved by the United States Food and Drug Administration (FDA) to treat chemotherapy-induced neutropenia. The FDA relied on the large literature database of nonclinical and clinical studies, as well as successful clinical trials to support approval of rHuG-CSF for this condition. rHuG-CSF also has utility for another indication: radiation-induced myelosuppression and treatment of potentially lethally irradiated personnel. rHuG-CSF showed significant efficacy in ameliorating the radiation-induced effects of myelosuppression. It enhanced survival from lethal radiation exposure within the hematopoietic subsyndrome (H) of the acute radiation syndrome (H-ARS) in all animal models evaluated.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Schuening FG, Storb R, Goehle S et al (1989) Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation. Blood 74:1308–1313
Patchen ML, MacVittie TJ, Solberg BD, Souza LM (1990) Therapeutic administration of recombinant human granulocyte colony stimulating factor accelerated hemopoietic regeneration and enhances survival in a murine model of radiation-induced myelosuppression. Int J Cell Cloning 8:107–122
MacVittie TJ, Monroy RL, Patchen ML, Souza LM (1990) Therapeutic use of recombinant human G-CSF in a canine model of sublethal and lethal whole-body irradiation. Int J Radiat Biol 57:723–736
Patchen ML, Fischer R, MacVittie TJ (1993) Effects of combined administration of IL-6 and G-CSF on recovery from radiation-induced hemopoietic aplasia. Exp Hematol 21:338–344
Schuening FG, Appelbaum FR, Deeg HJ et al (1993) Effects of recombinant canine stem cell factor, a c-kit ligand and recombinant granulocyte colony stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. Blood 81:20–26
Tanikawa S, Nakao I, Tsuneska K, Nobio N (1989) Effects of recombinant granuloctye colony-stimulating factor (rG- CSF) and recombinant granuloctye-macrophage colony-stimulating factor (rGM-CSF) on acute radiation hematopoietic injury in mice. Exp Hematol 17:883–888
Tanikawa S, Nose M, Yoshiro A, Tsuneoka K, Shikita M, Nara N (1990) Effects of recombinant human granuloctye colony-stimulating factor on the hematologic recovery and survival of irradiated mice. Blood 76:445–449
Farese AM, Hunt P, Grab LB, MacVittie TJ (1996) Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. J Clin Invest 97:2145–2151
MacVittie TJ, Farese AM, Herodin F, Grab LB, Baum CM, McKearn JP (1996) Combination therapy of radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor. Blood 87:4129–4135
MacVittie TJ, Farese AM, Jackson WI (2005) Defining the full therapeutic potential of recombinant growth factors in the post radiation-accident environment: the effect of supportive care plus administration of G-CSF. Health Phys 89:546–555
Mackey M, Aprikyan AAG, Dale DC (2003) The rate of apoptosis in post mitotic neutrophil precursors of normal and neutropenic humans. Cell Prolif 36:27–34
Lord BI, Woolford LB, Molineux G (2001) Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (peg-r-metHu G-CSF). Clin Cancer Res 7:2085–2090
Lord BI, Bronchud MH, Owens S et al (1989) The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci U S A 86:9499–9503
Rieger MA, Hoppe PS, Smejkal BM, Eitelhuber AC, Schroeder T (2009) Hematopoietic cytokines can instruct lineage choice. Science 325:217–218
Dainiak N (1997) Biological effects of radiation injury. 12(Suppl 2), iii–iv. In: Dainiak N, Schull WJ, Karkanitsa L, Aleinikova OA (eds) Radiation injury and the Chernobyl catastrophe. Miamisburg, OH, AlphaMed Press, 3-22-1996
Ricks RC, Fry SA (1990) The medical basis for radiation accident preparedness II: clinical experience and follow-up since, 1979. Elsevier Science, New York, NY
Browne D, Weiss JF, MacVittie TJ, Pillai MV (1990) Treatment of radiation injuries. Proceedings of the first consensus development conference on the treatment of radiation injuries, Plenum Press, New York
MacVittie TJ, Weiss JF, Browne D (1996) Advances in the treatment of radiation injuries. Proceedings of second consensus development conference on the treatment of radiation injuries, Pergamon, Elsevier Science Inc, Terrytown, NY
Ricks RC, Berger ME, O’Hara F (2001) The medical basis for radiation accident preparedness IV: clinical care of victims. Parthenon Publishers, Washington, DC
Waselenko JK, MacVittie TJ, Blakely WF et al (2004) Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med 140:1037–1051
Crawford LM (2002) New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Fed Regist 67:37988–37998. 5-31-2002. 21 CFR parts 314 and 601, FDA, HHS; ACTION: Final Rule
Food and Drug Administration, Center for Drug Evaluation and Research and Food and Drug Administration, Center for Biologics Evaluation and Research (2009) Guidance for industry: animal models-essential elements to address efficacy under the animal rule, 1–19, 1-13-2009
Anno GH, Young RW, Bloom RM, Mercier JR (2003) Dose response relationships for acute ionizing-radiation lethality. Health Phys 84:565–575
Anno GH, Baum SJ, Withers HR, Young RW (1989) Symptomatology of acute radiation effects in humans after exposure to doses of 0.5-30 Gy. Health Phys 56:821–838
Baranov AE, Guskova AK (1990) Acute radiation disease in Chernobyl accident victims. In: Ricks RC et al (eds) The medical basis for radiation accident preparedness II; clinical experience and follow-up since 1979. Elsevier, New York, pp 79–87
Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340
Hughes WT, Armstrong D, Bodey GP et al (1990) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161:381–396
Hughes WT (2002) Use of antimicrobial agents for treatment of infection in the neutropenic immunocompromised patient. In: Ricks R et al (eds) The medical basis for radiation-accident preparedness. The clinical care of victims. The Parthenon Publishing Group, Washington, DC, pp 117–129
Gafter-Gvili A, Fraser A, Mical P, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979–995
Schimpff SC (1990) Infections in radiation accidents. In: Browne D et al (eds) Treatment of radiation injuries. Plenum, New York, pp 75–85
Timmer-Bonte JN, de Boo TM, Smit HJ et al (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylatic antibiotics plus or minus granulocyte colony-stimulating factor in small cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 23:7974–7984
Pizzo PA (1984) Granulocytopenia and cancer therapy. Cancer 54:2649–2661
Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323–1332
Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751
National Comprehensive Cancer Network (2005) Clinical practice guidelines in oncology: fever and neutropenia. Version 1.2005. 8-31-2005
Hughes WT, Armstrong D, Bodey GP et al (1997) 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 25:551–573
Baranov AE, Konchalovski MV, Soloviev WY, Guskova AK (1998) Use of blood cell count changes after radiation exposure in dose assessment and evaluation of bone marrow function. In: Ricks RC et al (eds) The medical basis for radiation accident preparedness II. Elsevier, New York, pp 427–443
Baranov AE (1996) Allogenic bone marrow transplantation after severe, uniform total-body irradiation: experience from recent (Nyasvizh, Belarus) and previous radiation accidents. In: MacVittie TJ et al (eds) Advances in the treatment of radiation injuries: advances in the bioscience, vol 94. Pergamon, Elsevier Science Ltd, Tarrytown, NY, pp 281–293
Fliedner TM et al (1988) Hematological indicators to predict patient recovery after whole-body irradiation as a basis for clinical management. In: Ricks RC (ed) The medical basis for radiation accident preparedness. Elsevier, New York, pp 445–459
Toda H, Murata A, Matsuura N et al (1993) Therapeutic efficacy of granulocyte colony-stimulating factor against rat cecal ligation and puncture model. Stem Cells 11:228–234
Weisbart RH, Gasson JC, Golde DW (1989) Colony-stimulating factors and neutrophils. Colony-stimulating factors and host defense. Ann Intern Med 110:297–303
Cohen AM, Zsebo KM, Inoue H et al (1987) In vivo stimulation of granulopoiesis by recombinant human granulocyte colony-stimulating factor. Proc Natl Acad Sci USA 84:2484–2488
Matsumoto M, Matsubara S, Matsuno T et al (1987) Protective effect of human granulocyte colony-stimulating factor on microbial infection in neutropenic mice. Infect Immunol 55:2715–2720
Shinomiya N, Tsuru S, Katsura Y, Kayashima S, Nomoto K (1991) Enhanced resistance against Listeria monocytogenes achieved by pretreatment with granulocyte colony-stimulating factor. Infect Immunol 59:4740–4743
Wakiyama H, Tsuru S, Hata N et al (1993) Therapeutic effect of granulocyte colony-stimulating factor and cephem antibiotics against experimental infections in neutropenic mice induced by cyclophosphamide. Clin Exp Immunol 92:218–224
O’Reilly M, Silver GM, Greenhalgh DG, Gamelli RL, Davis JH, Hebert JC (1992) Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. J Trauma 33:679–682
Matsumoto M, Matsubara S, Yokota T (1991) Effect of combination therapy with recombinant granulocyte colony-stimulating factor (rG-CSF) and antibiotics in neutropenic mice unresponsive to antibiotics alone. J Antimicrob Chemother 28:447–453
Ono M, Matsumoto M, Matsubara S, Tomioka S, Asano S (1988) Protective effect of human granulocyte colony-stimulating factor on bacterial and fungal infections in neutropenic mice. Behring Inst Mitt 83:216–221
Lindemann A, Riedel D, Oster W et al (1988) Granulocyte/macrophage colony-stimulating factor induces interleukin-1 production by human polymorphonuclear neutrophils. J Immunol 140:837–839
Lindemann A, Riedel D, Oster W, Ziegler-Heitbrock HW (1989) Granulocyte-macrophage colony-stimulating factor induces cytokine secretion by human polymorphonuclear leukocytes. J Clin Invest 83:1308–1312
Lloyd AR, Oppenheim JJ (1992) Poly’s lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. Immunol Today 13:169–172
Fasano MB, Cousart S, Neal S, McCall CE (1991) Increased expression of the interleukin-1 receptor on blood neutrophils of human with the sepsis syndrome. J Clin Invest 88:1452–1459
McColl SR, Paquin R, Manard C, Beaulieu AD (1992) Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colony-stimulating factor and tumor necrosis factor. J Exp Med 176:593–598
Porteu F, Nathan C (1990) Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 172:599–607
Re F, Megozzi M, Muzio M, Dinarello CA, Mantovani A, Colotta F (1993) Expression of interleukin-1 receptor antagonist (IL-1ra) by human circulating polymorphonuclear cells. Eur J Immunol 23:570–573
Dinarello CA (2010) IL-1: discoveries, controversies and future directions. Eur J Immunol 40:606
Dinarello CA, Wolff RL (1974) Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci U S A 74:4624–4627
Strieter RM, Kunkel SL, Bone RC (1993) Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 21:S447–S463
Beutler B, Grau G (1993) Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med 21:S423–S435
Kobayashi Y, Okabe T, Urabe A, Suzukci N, Takaku F (1987) Human granulocyte colony stimulating factor produced by Escherichia coli shortens the period of granulocytopenia induced by irradiation in mice. Jpn J Cancer Res 78:763–768
Fushiki M, Ono K, Sasai K et al (1990) Effect of recombinant human granulocyte colony stimulating factor on granulocytopenia in mice induced by irradiation. Int J Radiat Oncol Biol Phys 18:353–357
Farese AM, Roskos L, Cheung E, Stead RB, Yin SM, MacVittie TJ (1998) A single administration of r-metHuG-SD/01 (SD01) significantly improves neutrophil recovery following autologous bone marrow transplantation. Blood 92:112
MacVittie TJ, Monroy RL (1990) Rescue of lethally irradiated animals: therapeutic use of rhG-CSF and rhGM-CSF in preclinical models of radiation-induced marrow aplasia. In: Browne D et al (eds) Treatment of radiation injuries. Plenum, New York, pp 35–49
Patchen ML, MacVittie T (1994) Granulocyte colony-stimulating factor and amifostine (Ethyol) synergize to enhance hemopoietic reconstitution and increase survival in irradiated animals. Semin Oncol 21:26–32
MacVittie TJ, Monroy R, Vigneulle RM, Zeman GH, Jackson WE (1991) The relative biological effectiveness of mixed fission-neutron:gamma radiation on the hematopoietic syndrome in the canine: effect of therapy on survival. Radiat Res 128:S29–S36
Nash RA, Schuening FG, Seidel K et al (1994) Effect of recombinant canine granulocyte-macrophage colony-stimulating factor of hematopoietic recovery after otherwise lethal total body irradiation. Blood 83:1963–1970
Neelis KJ, Dubbelman YD, Qingliang L, Thomas GR, Eaton DL, Wagemaker G (1997) Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. Exp Hematol 25:1084–1093
Neelis KJ, Hartong SCC, Egeland T, Thomas GR, Eaton DL, Wagemaker G (1997) The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys. Blood 90:2565–2573
Farese AM, Casey DB, Smith WG, Vigneulle RM, McKearn JP, MacVittie TJ (2001) Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in nonhuman primate model of radiation-induced myelosuppression: effect of schedule, dose, and route of administration. Stem Cells 19:522–533
Farese AM, Kirschner KF, Patchen ML, Zsebo KM, MacVittie TJ (1993) The effect of recombinant canine stem cell factor and/or recombinant canine granulocyte colony stimulating factor on marrow aplasia recovery in lethally irradiated canines. Exp Hematol 21:1169
Meisenberg BR, Davis TA, Melaragno AJ, Stead R, Monroy RL (1992) A comparison of therapeutic schedules for administering granulocyte colony-stimulating factor to nonhuman primates after high-dose chemotherapy. Blood 79:2267–2272
Barrett A (1984) Total body irradiation and LD 50 in man. In: Roerse JJ et al (eds) Response of different species to total body irradiation. Martinus Nijhoff Publishers, Dordrecht, The Netherlands, pp 205–208
Barabanova AV (1995) Acute radiation syndrome with cutaneous syndrome. In: Lord BI et al (eds) Radiation toxicology: bone marrow and leukaemia. Taylor and Francis, Bristol, PA, p 217
Konchalovsky MV, Baranov AE, Kolganov AV (2005) Multiple organ involvement and failure: selected Russian radiation accident cases re-visited. BJR Suppl. 2005; 27:26–29
Uozaki H, Fukayama M, Nakagawa K et al (2005) The pathology of multi-organ involvement: two autopsy cases from the Tokai-mura criticality accident. Br J Radiol 27:13–16
Asano S (2005) Multi-organ involvement: lessons from the experience of one victim of the Tokai-mura criticality accident. Br J Radiol 27:9–12
Densow D, Kindler H, Baranov AE, Tibken B, Hofer EP, Fliedner TM (1997) Criteria for the selection of radiation accident victims for stem cell transplantation. Stem Cells 15(suppl 2):287–297
Georges G, Storb R (2001) Experimental and clinical experience with hematopoietic stem cell transplants. In: Ricks R et al (eds) The medical basis for radiation-accident preparedness. Parthenon Publishing Group, Boca Raton, pp 73–93
Georges GE, Storb RF (1997) Experimental and clinical experience with hematopoietic stem cell transplants. Stem Cells 15:73–94
Fliedner TM, Kindler H, Densow D, Baranov AE, Guskova AK, Szepesi T (1996) The Moscow-Ulm radiation accident clinical history data base. In: MacVittie T et al (eds) Advances in the treatment of radiation injuries. Pergamon, New York, pp 271–279
Baranov AE, Selidovkin GD, Butturini A, Gale RP (1994) Hematopoietic recovery after 10-Gy acute total body radiation. Blood 83:596–599
Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205
Aapro MS, Cameron DA, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidents of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433–2453
United States Centers for Disease Control and Prevention (2005) Facts about Neupogen. Available at: http://emergency.cdc.gov/radiation/neupogenfacts.asp. Accessed 23 Nov 2010
United States Department of Health and Human Services (2010) Radiation emergency medical management; Hematopoietic subsyndromes; Hematopoeitic countermeasures. http://www.remm.nlm.gov/cytokines.htm. Accessed 22 Nov 2010
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Basel AG
About this chapter
Cite this chapter
Farese, A.M., Cohen, M.V., MacVittie, T.J. (2012). Recombinant Human G-CSF Enhances Recovery and Improves Survival from Severe Radiation-Induced Myelosuppression. In: Molineux, G., Foote, M., Arvedson, T. (eds) Twenty Years of G-CSF. Milestones in Drug Therapy. Springer, Basel. https://doi.org/10.1007/978-3-0348-0218-5_19
Download citation
DOI: https://doi.org/10.1007/978-3-0348-0218-5_19
Published:
Publisher Name: Springer, Basel
Print ISBN: 978-3-0348-0217-8
Online ISBN: 978-3-0348-0218-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)